Cargando…

Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin

BACKGROUND AND AIMS: Histological remission has arisen as the optimal treatment outcome in ulcerative colitis (UC). The aim of this retrospective study was to explore the diagnostic performance of the noninvasive fecal biomarkers calprotectin (FC) and lactoferrin (FL) compared to the histological in...

Descripción completa

Detalles Bibliográficos
Autores principales: Langhorst, Jost, Kairey, Lana, Oberle, Angela, Boone, James, Dobos, Gustav, Juette, Hendrik, Tannapfel, Andrea, Rueffer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802191/
https://www.ncbi.nlm.nih.gov/pubmed/36776494
http://dx.doi.org/10.1093/crocol/otaa053
_version_ 1784861632776634368
author Langhorst, Jost
Kairey, Lana
Oberle, Angela
Boone, James
Dobos, Gustav
Juette, Hendrik
Tannapfel, Andrea
Rueffer, Andreas
author_facet Langhorst, Jost
Kairey, Lana
Oberle, Angela
Boone, James
Dobos, Gustav
Juette, Hendrik
Tannapfel, Andrea
Rueffer, Andreas
author_sort Langhorst, Jost
collection PubMed
description BACKGROUND AND AIMS: Histological remission has arisen as the optimal treatment outcome in ulcerative colitis (UC). The aim of this retrospective study was to explore the diagnostic performance of the noninvasive fecal biomarkers calprotectin (FC) and lactoferrin (FL) compared to the histological indices Nancy Index (NI) and Riley Index (RI). METHODS: This study is a retrospective diagnostic accuracy study based on secondary analysis of patient data from 2002 to 2017 extracted from medical registries of our clinics in Essen-Mitte, Germany. Patients with UC underwent a colonoscopy, with biopsies taken from the rectum and the sigmoid scored by 2 experienced pathologists according to NI and RI and provided a stool sample within 7 days pre- or post-colonoscopy. Diagnostic accuracy of recommended cutoffs for FC (>50 μg/g) and FL (≥7.25 μg/g) were tested against our reference standard (NI ≥2) in terms of specificity, sensitivity, positive predictive value, negative predictive value, and accuracy (effectiveness). RESULTS: The number of patients with UC recruited was n = 226, aged 45.2 (SD 13.3). Histological indices were highly correlated (r = 0.980, P < 0.001). Fecal biomarkers correlated moderately with NI (FC: r = 0.383, P < 0.001; FL: r = 0.420, P < 0.001) and RI (FC: r = 0.395, P < 0.001; FL: r = 0.424, P < 0.001). Fecal biomarker concentrations were increased in patients with active histological disease (NI ≥2), median [IQR], FC 69.72 [20.07–254.38], FL 18.59 [6.06–44.42], compared to those with inactive disease (NI ≤1), FC 12.35 [3.89 – 32.16], FL 3.14 [0.75–11.05], z = −6.60, P < 0.001. Fecal biomarker concentrations differed significantly across NI grades 0–4 (FC: H(4) = 45.2; FL: H(4) = 47.5, both P < 0.001). Patients with grade 0 had significantly lower concentrations of fecal biomarkers than those with grade 3 (median; FC 10.94 vs 72.22; FL 2.30 vs 29.10; both P < 0.001) or grade 4 (FC 10.94 vs 67.00; FL 2.30 vs 27.64; both P < 0.001), as well as grade 2 for FC only (10.94 vs 56.22, P = 0.001). Concentrations were also lower in patients with grade 1 compared to those with grade 3 (FC 17.49 vs 72.22; FL 4.24 vs. 29.10; both P ≤ 0.001) or grade 4 (FC 17.49 vs 67.00; FL 4.24 vs 27.64; both P < 0.001). Receiver operating characteristics area under the curve showed moderate diagnostic accuracy for both FC 0.76 (95% confidence interval [CI] 0.70–0.83) and FL 0.73 (95% CI 0.66–0.80). Optimized cutoffs for both FC (≥34.29) and FL (≥5.85 μg/g) had slightly improved accuracy, compared with the manufacturer’s cutoffs (FC: 69.9% vs 65.9%; FL: 71.7% vs 69.0%). CONCLUSIONS: Fecal biomarkers calprotectin and lactoferrin correlate with histological disease activity and differentiate between patients in histological remission from those with evidence of moderate to severe disease activity. Their noninvasiveness, in addition to being inexpensive, supports their use in the clinical monitoring of patients with UC.
format Online
Article
Text
id pubmed-9802191
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98021912023-02-10 Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin Langhorst, Jost Kairey, Lana Oberle, Angela Boone, James Dobos, Gustav Juette, Hendrik Tannapfel, Andrea Rueffer, Andreas Crohns Colitis 360 Observations and Research BACKGROUND AND AIMS: Histological remission has arisen as the optimal treatment outcome in ulcerative colitis (UC). The aim of this retrospective study was to explore the diagnostic performance of the noninvasive fecal biomarkers calprotectin (FC) and lactoferrin (FL) compared to the histological indices Nancy Index (NI) and Riley Index (RI). METHODS: This study is a retrospective diagnostic accuracy study based on secondary analysis of patient data from 2002 to 2017 extracted from medical registries of our clinics in Essen-Mitte, Germany. Patients with UC underwent a colonoscopy, with biopsies taken from the rectum and the sigmoid scored by 2 experienced pathologists according to NI and RI and provided a stool sample within 7 days pre- or post-colonoscopy. Diagnostic accuracy of recommended cutoffs for FC (>50 μg/g) and FL (≥7.25 μg/g) were tested against our reference standard (NI ≥2) in terms of specificity, sensitivity, positive predictive value, negative predictive value, and accuracy (effectiveness). RESULTS: The number of patients with UC recruited was n = 226, aged 45.2 (SD 13.3). Histological indices were highly correlated (r = 0.980, P < 0.001). Fecal biomarkers correlated moderately with NI (FC: r = 0.383, P < 0.001; FL: r = 0.420, P < 0.001) and RI (FC: r = 0.395, P < 0.001; FL: r = 0.424, P < 0.001). Fecal biomarker concentrations were increased in patients with active histological disease (NI ≥2), median [IQR], FC 69.72 [20.07–254.38], FL 18.59 [6.06–44.42], compared to those with inactive disease (NI ≤1), FC 12.35 [3.89 – 32.16], FL 3.14 [0.75–11.05], z = −6.60, P < 0.001. Fecal biomarker concentrations differed significantly across NI grades 0–4 (FC: H(4) = 45.2; FL: H(4) = 47.5, both P < 0.001). Patients with grade 0 had significantly lower concentrations of fecal biomarkers than those with grade 3 (median; FC 10.94 vs 72.22; FL 2.30 vs 29.10; both P < 0.001) or grade 4 (FC 10.94 vs 67.00; FL 2.30 vs 27.64; both P < 0.001), as well as grade 2 for FC only (10.94 vs 56.22, P = 0.001). Concentrations were also lower in patients with grade 1 compared to those with grade 3 (FC 17.49 vs 72.22; FL 4.24 vs. 29.10; both P ≤ 0.001) or grade 4 (FC 17.49 vs 67.00; FL 4.24 vs 27.64; both P < 0.001). Receiver operating characteristics area under the curve showed moderate diagnostic accuracy for both FC 0.76 (95% confidence interval [CI] 0.70–0.83) and FL 0.73 (95% CI 0.66–0.80). Optimized cutoffs for both FC (≥34.29) and FL (≥5.85 μg/g) had slightly improved accuracy, compared with the manufacturer’s cutoffs (FC: 69.9% vs 65.9%; FL: 71.7% vs 69.0%). CONCLUSIONS: Fecal biomarkers calprotectin and lactoferrin correlate with histological disease activity and differentiate between patients in histological remission from those with evidence of moderate to severe disease activity. Their noninvasiveness, in addition to being inexpensive, supports their use in the clinical monitoring of patients with UC. Oxford University Press 2020-06-27 /pmc/articles/PMC9802191/ /pubmed/36776494 http://dx.doi.org/10.1093/crocol/otaa053 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Observations and Research
Langhorst, Jost
Kairey, Lana
Oberle, Angela
Boone, James
Dobos, Gustav
Juette, Hendrik
Tannapfel, Andrea
Rueffer, Andreas
Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
title Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
title_full Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
title_fullStr Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
title_full_unstemmed Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
title_short Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
title_sort assessing histological inflammatory activity in patients with ulcerative colitis: a diagnostic accuracy study testing fecal biomarkers lactoferrin and calprotectin
topic Observations and Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802191/
https://www.ncbi.nlm.nih.gov/pubmed/36776494
http://dx.doi.org/10.1093/crocol/otaa053
work_keys_str_mv AT langhorstjost assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT kaireylana assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT oberleangela assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT boonejames assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT dobosgustav assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT juettehendrik assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT tannapfelandrea assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin
AT ruefferandreas assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin